Back to results
CompletedPhase 2

Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

NCT02061085

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Zaragoza, Aragon, Spain

+10 additional locations

View on ClinicalTrials.gov
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment — TrialFind